Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2001 Oct 9;98(21):12191-6.
doi: 10.1073/pnas.211445998. Epub 2001 Oct 2.

Suppressor of cytokine signaling 3 (SOCS-3) protects beta -cells against interleukin-1beta - and interferon-gamma -mediated toxicity

Affiliations

Suppressor of cytokine signaling 3 (SOCS-3) protects beta -cells against interleukin-1beta - and interferon-gamma -mediated toxicity

A E Karlsen et al. Proc Natl Acad Sci U S A. .

Abstract

Suppressor of cytokine signaling 3 (SOCS-3) is a negative feedback regulator of IFN-gamma signaling, shown up-regulated in mouse bone marrow cells by the proinflammatory cytokines interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha), and IFN-gamma. IL-1beta and IFN-gamma alone, or potentiated by TNF-alpha, are cytotoxic to the insulin producing pancreatic beta-cells and beta-cell lines in vitro and suggested to contribute to the specific beta-cell destruction in Type-1 diabetes mellitus (T1DM). Using a doxycycline-inducible SOCS-3 expression system in the rat beta-cell line INS-1, we demonstrate that the toxic effect of both IL-1beta or IFN-gamma at concentrations that reduced the viability by 50% over 3 days, was fully preventable when SOCS-3 expression was turned on in the cells. At cytokine concentrations or combinations more toxic to the cells, SOCS-3 overexpression yielded a partial protection. Whereas SOCS-3-mediated inhibition of IFN-gamma signaling is described in other cell systems, SOCS-3 mediated inhibition of IL-1beta signaling has not previously been described. In addition we show that SOCS-3 prevention of IL-1beta-induced toxicity is accompanied by inhibited transcription of the inducible nitric oxide synthase (iNOS) by 80%, resulting in 60% decreased formation of the toxic nitric oxide (NO). Analysis of isolated native rat islets exposed to IL-1beta revealed a naturally occurring but delayed up-regulated SOCS-3 transcription. Influencing SOCS-3 expression thus represents an approach for affecting cytokine-induced signal transduction at a proximal step in the signal cascade, potentially useful in future therapies aimed at reducing the destructive potential of beta-cell cytotoxic cytokines in T1DM, as well as other cytokine-dependent diseases.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Inducible SOCS-3 expression in the INS-r3#2 clone. A clear induction of SOCS-3 mRNA measured by RNase protection assay was induced by increasing concentrations of doxycycline (A), with a maximal induction, relative to the internal standard cyclophilin (Cyclo), obtained at 0.5–1 μg/ml doxycycline. The induced mRNA correlated well with the induced SOCS-3 protein measured by Western blot (B).
Figure 2
Figure 2
Effect of recombinant SOCS-3 expression on cytokine-mediated β-cell impairment. Viability was determined by the MTT assay in INS-r3#2 cells cultured in the absence or presence of cytokines for 3 days, with or without 0.5 μg/ml doxycycline-induced SOCS-3 expression, starting 1 day before exposure to the cytokines. (A) The cells were exposed to TNF-α (200 units/ml), IFN-γ (200 units/ml), IL-1β (150 pg/ml), 10× IL-1β (1500 pg/ml), or the mix of all three cytokines (200 units/ml, 200 units/ml, and 150 pg/ml, respectively). The INS-r3#2 cells were exposed to IFN-γ (B; 200 units/ml, n = 3) and to IFN-γ + IL-1β (C; 200 units/ml and 150 pg/ml, respectively, n = 5), in the presence of increasing concentrations of doxycycline. Data are mean values ± SD. Significant P values are indicated in A and in Results.
Figure 3
Figure 3
Effect of recombinant SOCS-3 expression on cytokine-induced NO production in INS-r3#2 cells. NO production (measured as accumulated nitrite; A) was determined from the same experimental conditions detailed in Fig. 2A. (B) A dose-dependent reduction of NO production in response to increasing doxycycline concentration is shown for the INS-r3#2 cells exposed to IL-1β (150 pg/ml) for 3 days. Data are mean values ± SD of three separate experiments. Significant P values are indicated in A.
Figure 4
Figure 4
Effect of recombinant SOCS-3 expression on IL-1β-induced iNOS promoter activity. Following transfection with an iNOS promoter construct, promoter activity was measured in INS-r3#2 cells (A) or the parental INS-1 cells (B) exposed to increasing concentrations of IL-1β in the absence (white bars) or presence (black bars) of doxycyclin. INOS promoter activity induced by 150 pg/ml IL-1β in the absence of doxycycline is set to 100% for both cell lines. Data are mean ± SD for n = 3.
Figure 5
Figure 5
SOCS-3 inhibited IFN-γ phosphorylation-dependent activation of STAT-1 signaling. EMSA of nuclear extracts demonstrated activation of STAT-1 following IFN-γ exposure of both the parental INS-1 cell line and the INS-r3#2 clone (A), which was clearly inhibited when SOCS-3 was induced by 1 μg/ml doxycycline in the INS-r3#2 clone. STAT-1 specificity of the activated STAT is evident from supershifting only by the STAT-1 specific antibody (B). In addition, only a competition with a specific oligo (sc) and not with a nonspecific oligo (nsc) was detected.
Figure 6
Figure 6
SOCS-3 mRNA expression in rat islets exposed to IL-1β. Rat islets were exposed to different concentrations of IL-1β for 1 or 24 h and semiquantitative analysis of SOCS-3 mRNA expression relative to the internal standard TBP was performed. Data are mean ± SD of n = 5–10 separate experiments. *, P ≤ 0.01 and **, P ≤ 0.001 compared with control at 24 h, and +, P ≤ 0.001 between 1 and 24 h exposure to 1500 pg/ml IL-1β.

Similar articles

Cited by

References

    1. Mandrup-Poulsen T, Bendtzen K, Nerup J, Dinarello C A, Svenson M, Nielsen J H. Diabetologia. 1986;29:63–67. - PubMed
    1. Bendtzen K, Mandrup-Poulsen T, Nerup J, Nielsen J H, Dinarello C A, Svenson M. Science. 1986;232:1545–1547. - PubMed
    1. Mandrup-Poulsen T, Egebjerg J, Nerup J, Bendtzen K, Nielsen J, Dinarello C. Acta Pathol Microbiol Immunol Scand Sect C. 1987;95:55–63. - PubMed
    1. Nerup J, Mandrup-Poulsen T, Helqvist S, Andersen H U, Pociot F, Reimers J I, Cuartero B G, Karlsen A E, Bjerre U, Lorenzen T. In: New Horizons in Diabetes Mellitus and Cardiovascular Disease. Schwartz C J, Born G V R, editors. London: Science Press; 1995. pp. 57–63.
    1. Eizirik D L, Flodström M, Karlsen A E, Welsh N. Diabetologia. 1996;39:875–890. - PubMed

Publication types

MeSH terms

Substances